Trial Protocol ID
USOR 23229_TTX-030-003

Investigator
Mohit Narang, M.D.

An open-label multicenter 3-arm randomized Phase 2 study to assess the efficacy and safety of TTX-030 and chemotherapy with or without budigalimab, compared to chemotherapy alone, for the treatment of patients not previously treated for metastatic pancreatic adenocarcinoma

Trial Protocol ID
USOR 22133_C-800-22

Investigator
Yousuf A. Gaffar, M.D.

A PHASE II RANDOMIZED, OPEN-LABEL, TRIAL OF NAB-PACLITAXEL +GEMCITABINE WITH OR WITHOUT BOTENSILIMAB (Agen1181) IN PATIENTS WITH METASTATIC PANCREATIC CANCER WHO HAVE PROGRESSED ON PRIOR 5FU + LEUCOVORIN+ IRINOTECAN +OXALIPLATIN (FOLFIRINOX)

Trial Protocol ID
USOR 22033_TT420C1206 *STAR*

A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma

Trial Protocol ID
USOR 22123_1403-0011_Brightline-2 *STAR*

A Phase IIa/IIb, open-label, single-arm, multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours

Trial Protocol ID
USOR 22093_XB002-101_Jewel-101

Investigator
Yousuf A. Gaffar, M.D.

A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 AS SINGLE-AGENT AND COMBINATION THERAPY IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (XB002-101)